secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001714899-25-000077
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali initiates rolling BLA submission for tividenofusp alfa (Hunter syndrome); launch targeted late 2025/early 2026
--------------------------------------------------------------------------------

- Rolling BLA for accelerated approval of tividenofusp alfa (MPS II) initiated; FDA aligned on CSF HS as surrogate endpoint.
- BLA submission expected to complete in first half of May 2025.
- Potential U.S. commercial launch in late 2025 or early 2026.
- FDA collaboration under START program for accelerated development path of DNL126 (Sanfilippo syndrome).
- Productive engagement with CDER on full approval conversion path for tividenofusp alfa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000077/0001714899-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000077/dnli-20250402.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer